Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - AccuredReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Kura Oncology (KURA) Long-Term Debt Issuances (2010 - 2015)

Kura Oncology (KURA) reported Long-Term Debt Issuances of $710000.0 for Q1 2015, down 64.5% on a QoQ basis from $2.0 million in Q4 2014.

Kura Oncology (KURA) has 5 years of Long-Term Debt Issuances data on file, last reported at $710000.0 in Q1 2015.

  • Quarterly Long-Term Debt Issuances changed N/A year-over-year to $710000.0 in Q1 2015, while the trailing twelve-month figure through Dec 2015 was $710000.0 (down 66.19% YoY) and the FY2022 annual result came in at $10.0 million, changed N/A from the prior year.
  • Long-Term Debt Issuances eased to $710000.0 in Q1 2015 per KURA's latest filing, from $2.0 million in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $2.0 million in Q4 2014 and bottomed at $25000.0 in Q1 2012.
  • The 4-year median for Long-Term Debt Issuances is $100000.0 (2014), against an average of $572000.0.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 2.73 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Kura Oncology 801.92 Mn 801.92 Mn 18.00 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2015 710,000.00
Mar 31, 2015 710,000.00
Dec 31, 2014 2.00 Mn
Dec 31, 2014 2.00 Mn
Sep 30, 2014 100,000.00
Sep 30, 2014 100,000.00
Jun 30, 2013 25,000.00
Jun 30, 2013 25,000.00
Mar 31, 2012 25,000.00
Mar 31, 2012 25,000.00
Dec 31, 2010 25,000.00
Dec 31, 2010 25,000.00